Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharma (NQ: AMPH )

43.48 +0.74 (+1.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 328,465
Open 42.62
Bid (Size) 42.70 (1)
Ask (Size) 44.63 (1)
Prev. Close 42.74
Today's Range 42.19 - 43.60
52wk Range 38.43 - 67.66
Shares Outstanding 48,901,965
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Exploring NASDAQ:AMPH's growth characteristics.
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations 
Via Chartmill

Performance

YTD
-30.20%
-30.20%
1 Month
+8.56%
+8.56%
3 Month
-19.57%
-19.57%
6 Month
-22.15%
-22.15%
1 Year
-0.82%
-0.82%

More News

Read More
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
Via ACCESSWIRE
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
Via ACCESSWIRE
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
NASDAQ:AMPH, an undervalued stock with good fundamentals.
Via Chartmill
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
Via ACCESSWIRE
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
Via ACCESSWIRE
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
Via Benzinga
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
Via ACCESSWIRE
Delving into NASDAQ:AMPH's Growth Prospects.
Via Chartmill
Earnings Outlook For Amphastar Pharma
Via Benzinga
Is NASDAQ:AMPH a Fit for Growth Investing Strategies?
Via Chartmill
Is NASDAQ:AMPH a Fit for Growth Investing Strategies?
Via Chartmill
Unlocking the Growth Potential of NASDAQ:AMPH.
Via Chartmill
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024
Via ACCESSWIRE
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
Via Investor's Business Daily
3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential
Via InvestorPlace
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
Via Investor's Business Daily
Despite its impressive fundamentals, NASDAQ:AMPH remains undervalued.
Via Chartmill
What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition
Via Benzinga
NASDAQ:AMPH is not too expensive for the growth it is showing.
Via Chartmill
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.